If approved, the acquisition would combine two of the leading makers of heart-related devices. The deal will cost Abbott roughly $25 billion.
For Abbott, the acquisition represents a way for the company to enhance its position in the medical devices business and “gain a better negotiating position” with its hospital customers, according to a NASDAQ report.
Both organizations agreed to the partnership in April. They expect the deal to officially close in the fourth quarter.
More articles about transactions and valuations:
Washington Health System, UPMC strike cardiac surgery partnership
McLeod Heath to acquire Clarendon Health System
Yale New Haven, Lawrence & Memorial deal faces public scrutiny
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
